# A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

> **NCT00910858** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 40 (actual)

## Conditions studied

- Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Recombinant human erythropoietin

## Key facts

- **NCT ID:** NCT00910858
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-04
- **Final completion:** 2009-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910858, "A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00910858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*